ClinicalTrials.gg
CompletedNCT01066052Updated Dec 14, 2018Results posted

Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years

A Phase 4 interventional study of r-hGH in Turner's Syndrome, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in France. Open to female participants aged Up to 4 Years. Per ClinicalTrials.gov, last updated 2018-12-14.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 17 years 11 months after the study started (first participant enrolled Feb 1992, registered Feb 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
115
Allocation
Non-randomized
Ages
Up to 4 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.

Enrollment
7th of 14
115 · median 108
Started
1992
the only one that year
Phase 4
6 of 14
none open now
Registered
9th of 14
by date
Lead sponsor
2 of 14
Merck KGaA, Darmstadt, Germany

Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 7th largest by enrollment, is the only one that started in 1992, is one of 6 in phase 4, and was the 9th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: Up to 4 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing Human Growth Hormone in Turner Syndrome as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of recombinant human growth hormone (r-hGH) treatment in girls with Turner Syndrome under the age of 4 years. After 4 years of treatment, height in these girls will be compared with an historical control group of untreated girls with Turner Syndrome, matched for age and height at baseline.

03

Conditions studied

  • Turner's Syndrome

Browse trials for

Keywords

  • Growth hormone
  • Turner syndrome
  • r-hGH
  • early treatment
04

Who can participate

Ages eligible
Up to 4 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Young girls with turner syndrome proved by karyotype
  • Growth hormone secretion confirmed with ornithin stimulation test
  • Normal glucidic metabolism confirmed by assessment of
  • None associated severe pathology which could have impact on growth (i.e. renal insufficiency, decompensated heart failure)
  • No previous or associated treatment with anabolic or sexual
  • Known parental height

Exclusion criteria

Exclusion Criteria:

  • Severe associated pathology with impact on growth
  • Concomitant treatment with impact on growth
  • Previous or associated treatment with anabolic steroids
  • Associated growth hormone deficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    r-hGH

    Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.

    Drug: r-hGH

  • No intervention
    Historical Control

    This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.

Interventions

  • Drugr-hGH

    Subcutaneous administration.

    Also known as: Saizen®

06

What researchers measure

Primary outcomes

  1. Height SDS at Year 4

    Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.

    Time frame: Year 4

Secondary outcomes

  1. Number of Participants With Abnormal Glycated Hemoglobin (HbA1c) Levels

    HbA1c develops when hemoglobin, a protein within red blood cells that carries oxygen throughout the body, joins with glucose in the blood, becoming glycated. The higher the level of glucose in the blood, the higher the level of HbA1c is detectable on red blood cells. The normal range for HbA1c is 4 percent (%) to 5.9%. Number of participants, who had abnormal HbA1c levels any time during the assessment, were reported.

    Time frame: Baseline up to Year 2

  2. Difference Between Bone Age (BA) and Chronological Age (CA) (BA-CA)

    BA was determined using left wrist and hand X-ray. CA was determined using the date of birth. Difference of BA and CA (BA-CA) was reported.

    Time frame: Baseline, Year 1, Year 2

  3. Number of Participants With Anti r-hGH Antibodies

    Time frame: Baseline up to Year 2

  4. Number of Participants With Abnormal Insulin-Like Growth Factor 1 (IGF1) Levels

    The normal range for IGF1 levels is 45 to 117 nanogram per milliliter (ng/mL) for girls aged less than (\<) 3 years and 80 to 236 ng/mL for girls aged 3 to 6 years. Values outside the normal range were considered abnormal. Number of participants, who had abnormal IGF1 levels any time during the assessment, were reported.

    Time frame: Baseline up to Year 2

  5. Number of Participants Who Reached Normal Height at Year 4

    Participants with normal height were those who attained a height which was within +/- 2 height SDS of reference population standard. Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.

    Time frame: Year 4

07

Results

Posted Dec 14, 2018

Participant flow

Participant flow — Overall Study
MilestoneRecombinant Human Growth Hormone (r-hGH)Historical Control
Started6451
Treated610
Completed6151
Not completed30
Withdrew: Enrolled but not treated30

Outcome measures

PrimaryHeight SDS at Year 4

Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.

Time frame:
Year 4
Reported as:
Mean · standard deviation score
Height SDS at Year 4
standard deviation scorer-hGHHistorical Control
Height SDS at Year 4-1.35 ± 0.86-2.44 ± 0.73
SecondaryNumber of Participants With Abnormal Glycated Hemoglobin (HbA1c) Levels

HbA1c develops when hemoglobin, a protein within red blood cells that carries oxygen throughout the body, joins with glucose in the blood, becoming glycated. The higher the level of glucose in the blood, the higher the level of HbA1c is detectable on red blood cells. The normal range for HbA1c is 4 percent (%) to 5.9%. Number of participants, who had abnormal HbA1c levels any time during the assessment, were reported.

Time frame:
Baseline up to Year 2
Reported as:
Number · participants
Number of Participants With Abnormal Glycated Hemoglobin (HbA1c) Levels
participantsr-hGH
Number of Participants With Abnormal Glycated Hemoglobin (HbA1c) Levels1
SecondaryDifference Between Bone Age (BA) and Chronological Age (CA) (BA-CA)

BA was determined using left wrist and hand X-ray. CA was determined using the date of birth. Difference of BA and CA (BA-CA) was reported.

Time frame:
Baseline, Year 1, Year 2
Reported as:
Mean · months
Difference Between Bone Age (BA) and Chronological Age (CA) (BA-CA)
monthsr-hGH
Baseline-8.9 ± 7.5
Year 1-8.7 ± 6.5
Year 2-8.1 ± 7.8
SecondaryNumber of Participants With Anti r-hGH Antibodies
Time frame:
Baseline up to Year 2

No measurements were reported for this outcome.

SecondaryNumber of Participants With Abnormal Insulin-Like Growth Factor 1 (IGF1) Levels

The normal range for IGF1 levels is 45 to 117 nanogram per milliliter (ng/mL) for girls aged less than (\<) 3 years and 80 to 236 ng/mL for girls aged 3 to 6 years. Values outside the normal range were considered abnormal. Number of participants, who had abnormal IGF1 levels any time during the assessment, were reported.

Time frame:
Baseline up to Year 2
Reported as:
Number · participants
Number of Participants With Abnormal Insulin-Like Growth Factor 1 (IGF1) Levels
participantsr-hGH
Number of Participants With Abnormal Insulin-Like Growth Factor 1 (IGF1) Levels46
SecondaryNumber of Participants Who Reached Normal Height at Year 4

Participants with normal height were those who attained a height which was within +/- 2 height SDS of reference population standard. Height SDS was calculated as height minus reference mean height divided by standard deviation of the reference population. Height SDS reflects the height relative to a reference population of the same age and gender.

Time frame:
Year 4
Reported as:
Number · participants
Number of Participants Who Reached Normal Height at Year 4
participantsr-hGH
Number of Participants Who Reached Normal Height at Year 449

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
r-hGH—8/61 (13.1%)47/61 (77%)
Most frequent serious events
Most frequent serious events
Eventr-hGH
Urethral refluxVascular disorders1/61
Trauma leading to scalp surgerySurgical and medical procedures1/61
MeaslesSkin and subcutaneous tissue disorders1/61
Serious otitisNervous system disorders1/61
Immunoglobulin G4 deficiencyImmune system disorders1/61
Arterial hypertensionRespiratory, thoracic and mediastinal disorders1/61
Chronic persistent cytolysisCongenital, familial and genetic disorders1/61
Surgery to remove large mass (meningocele/benign cyst)Surgical and medical procedures1/61
Transtympanic drainage tube placementSurgical and medical procedures1/61
Tonsillectomy/adenoidectomySurgical and medical procedures1/61
Most frequent other events
Most frequent other events
Eventr-hGH
InfectionInfections and infestations47/61

Baseline characteristics

All Participants.

Age, Categorical
Age, Categorical(Participants)r-hGHHistorical ControlTotal
<=18 years6451115
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)r-hGHHistorical ControlTotal
Female6451115
Male000
08

Study locations

1 site
  • Hôpital Robert Debré
    Paris, 75935, France
09

References and documents

Publications

  • Linglart A, Cabrol S, Berlier P, Stuckens C, Wagner K, de Kerdanet M, Limoni C, Carel JC, Chaussain JL; French Collaborative Young Turner Study Group. Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol. 2011 Jun;164(6):891-7. doi: 10.1530/EJE-10-1048. Epub 2011 Mar 11. PubMed 21398400 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 1992 to primary completion in Mar 1999, 85 months.

Results were first posted in Dec 2018, 19 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2010
First posted
Feb 10, 2010
StartActual
Feb 29, 1992
Primary completionActual
Mar 31, 1999
CompletionActual
Aug 31, 2010
Results first posted
Dec 14, 2018
Last update
Dec 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01066052
Responsible party
Sponsor
First posted
Feb 10, 2010
Start date
Feb 29, 1992
Primary completion
Mar 31, 1999
Completion
Aug 31, 2010
Results posted
Dec 14, 2018
Last update
Dec 14, 2018

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion